Galectin Therapeutics (GALT)


Stock Update (NASDAQ:GALT): Galectin Therapeutics Inc Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis

Galectin Therapeutics Inc (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the screening of the first …

Company Update (NASDAQ:GALT): Galectin Therapeutics Inc Names Dr. Marc Rubin Lead Independent Director

Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that Marc Rubin, M.D.

Stock Update (NASDAQ:GALT): Galectin Therapeutics Inc Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that in an open-label Phase …

Stock Update (NASDAQ:GALT): Galectin Therapeutics Inc Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program

Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reported financial results for the three …

Company Update (NASDAQ:GALT): Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update

Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the …

Company Update (NASDAQ:GALT): Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH

Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it has engaged the contract research …

Stock Update (NASDAQ:GALT): Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02

Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces details of the design of its …

MLV Reiterates Buy On Galectin Therapeutics On The Back Of 3Q14 Update

In a research report sent to investors today, MLV analyst Vernon Bernardino reiterated a Buy rating on Galectin Therapeutics (NASDAQ:GALT) with a price …

MLV Maintains Buy On Galectin Therapeutics; Sees 194% Upside For The Stock

In a research report sent to investors today, MLV analyst Vernon Bernardino maintained a Buy rating on Galectin Therapeutics (NASDAQ:GALT) with a $16 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts